Research progress on biological agents in the treatment of ankylosing spondylitis
10.12206/j.issn.2097-2024.202502005
- VernacularTitle:生物制剂治疗强直性脊柱炎的研究进展
- Author:
Jie GAO
1
;
Xinlan LIN
2
;
Zhaoqian WANG
1
;
Qingting ZHANG
2
;
Jingjing LI
3
;
Feng ZHANG
3
,
4
Author Information
1. Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China.
2. School of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China.
3. School of Pharmacy, Anhui University of Chinese Medicine, Hefei 230012, China.
4. Department of Pharmacy, Second Affiliated Hospital of Naval Medical University, Shanghai 200003, China
- Publication Type:Reviews
- Keywords:
biological agents;
ankylosing spondylitis;
clinical application;
adverse effects
- From:
Journal of Pharmaceutical Practice and Service
2025;43(7):320-324
- CountryChina
- Language:Chinese
-
Abstract:
The pathogenesis of ankylosing spondylitis （AS） is usually insidious and has not been fully elucidated. Non-steroidal anti-inflammatory drugs （NSAIDs） and anti-rheumatic drugs （ARDs） are usually given to improve the condition. however, some patients still have poor results or adverse reactions from conventional treatments. Biological agents have significantly changed therapeutic strategies in the field of rheumatology since their clinical application was initiated and are gradually becoming the main therapeutic option for patients with AS. The current research progress on biologics in the treatment of AS in terms of the current treatment status, clinical problems, and solution strategies were reviewed, which could provide theoretical basis and reference with clinical value, and promote the precise treatment of AS in the future.
